Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Slope of the anterior mitral valve leaflet: A new measurement of
left ventricular unloading for left ventricular assist devices and
systolic dysfunction
Sara C. Martinez
Washington University School of Medicine in St. Louis

Elisa A. Bradley
Washington University School of Medicine in St. Louis

Eric L. Novak
Washington University School of Medicine in St. Louis

Ravi Rasalingam
Washington University School of Medicine in St. Louis

Ari M. Cedars
Washington University School of Medicine in St. Louis

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Martinez, Sara C.; Bradley, Elisa A.; Novak, Eric L.; Rasalingam, Ravi; Cedars, Ari M.; Ewald, Gregory A.;
Silvestry, Scott C.; and Joseph, Susan M., ,"Slope of the anterior mitral valve leaflet: A new measurement
of left ventricular unloading for left ventricular assist devices and systolic dysfunction." Texas Heart
Institute Journal. 41,3. 262-272. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2995

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Sara C. Martinez, Elisa A. Bradley, Eric L. Novak, Ravi Rasalingam, Ari M. Cedars, Gregory A. Ewald, Scott
C. Silvestry, and Susan M. Joseph

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/2995

Clinical
Investigation

Slope of the Anterior
Mitral Valve Leaflet:
A New Measurement of Left
Ventricular Unloading for Left Ventricular
Assist Devices and Systolic Dysfunction

Sara C. Martinez, MD, PhD
Elisa A. Bradley, MD
Eric L. Novak, MS
Ravi Rasalingam, MD
Ari M. Cedars, MD
Gregory A. Ewald, MD
Scott C. Silvestry, MD
Susan M. Joseph, MD

Key words: Echocardiography, Doppler/methods/
trends; health status
indicators; heart failure/
classification/physiopathology/therapy; heart-assist
devices; models, theoretical;
predictive value of tests;
reference values; sensitivity and specificity; severity
of illness index; ventricular
function/physiology
From: Department of Internal Medicine, Cardiovascular Division (Drs. Bradley,
Cedars, Ewald, Joseph,
Martinez, and Rasalingam;
and Mr. Novak), and Department of Surgery, Division
of Cardiothoracic Surgery
(Dr. Silvestry), Washington
University School of
Medicine in St. Louis,
St. Louis, Missouri 63110
Address for reprints:
Sara C. Martinez, MD,
660 S. Euclid Ave.,
Box 8086, St. Louis, MO
63110
E-mail:
smartinez@wustl.edu

© 2014 by the Texas Heart ®
Institute, Houston

262

Left ventricular assist device (LVAD)-supported patients are evaluated routinely with use of
transthoracic echocardiography. Values of left ventricular unloading in this unique patient
population are needed to evaluate LVAD function and assist in patient follow-up.
We introduce a new M-mode measurement, the slope of the anterior mitral valve leaflet (SLAM), and compare its efficacy with that of other standard echocardiographically
evaluated values for left ventricular loading, including E/ec and pulmonary artery systolic
pressures. Average SLAM values were determined retrospectively for cohorts of random,
non-LVAD patients with moderately to severely impaired left ventricular ejection fraction
(LVEF) (<0.35, n=60). In addition, pre- and post-LVAD implantation echocardiographic images of 81 patients were reviewed.
The average SLAM in patients with an LVEF <0.35 was 11.6 cm/s (95% confidence
interval, 10.4–12.8); SLAM had a moderately strong correlation with E/ec in these patients.
Implantation of LVADs significantly increased the SLAM from 7.3 r 2.44 to 14.7 r 5.01
cm/s (n=42, P <0.0001). The LVAD-supported patients readmitted for exacerbation of congestive heart failure exhibited decreased SLAM from 12 r 3.93 to 7.3 r 3.5 cm/s (n=6,
P=0.041). In addition, a cutpoint of 10 cm/s distinguished random patients with LVEF
<0.35 from those in end-stage congestive heart failure (pre-LVAD) with an 88% sensitivity
and a 55% specificity.
Evaluating ventricular unloading in LVAD patients remains challenging. Our novel Mmode value correlates with echocardiographic values of left ventricular filling in patients
with moderate-to-severe systolic function and dynamically improves with the ventricular
unloading of an LVAD. (Tex Heart Inst J 2014;41(3):262-72)

T

herapy with an implanted continuous-flow left ventricular assist device (CFLVAD) has improved survival rates and quality of life in patients with endstage heart failure by increasing cardiac output and decreasing left ventricular
(LV) preload.1-3 In non-LVAD–supported patients with heart failure, multiple transthoracic echocardiographic (TTE) methods exist for evaluating LV filling pressures,
including chamber dimensions, mitral valve inflow Doppler measurements, pulmonary venous Doppler measurements, and tissue Doppler velocities.4-6 In patients with
nonphysiologic unloading of the LV by a CF-LVAD, acquisition and interpretation
of the Doppler and echocardiographic images required for many of these accepted
methods might be challenging. Even in circumstances in which accurate Doppler
evaluation is possible, some studies in CF-LVAD patients have revealed that, although
E/ec ratio decreases after LVAD implantation, it correlates poorly with invasive measurements of pulmonary capillary wedge pressure (PCWP).7,8 Other guidelines are
therefore needed to supplement current knowledge toward evaluating LV unloading
and clinical status in CF-LVAD–supported patients.
The mitral valve is a fast-moving structure, the motion of which is best detected
with the superior temporal resolution of M-mode echocardiography in the parasternal
views.9 In the presence of elevated filling pressures, the anterior mitral leaflet tracing
in M-mode displays gradual closure after the peak of the A-wave in cardiac diastole,
as compared with brisk closure in patients with normal filling pressures.9 In extreme
cases, this closure process slows to the point where there is a recognizable “B-bump”
after atrial contraction, which for more than 40 years has been known to correlate with
significantly elevated LV end-diastolic pressure (LVEDP)— greater than 20 mmHg.10
Until now, the slope of the anterior mitral leaflet (SLAM) in end-diastole has never
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been measured or quantified. In the present study, we
examined the clinical usefulness of this phenomenon by
evaluating SLAM in randomly selected patients with
systolic heart failure, and in LVAD-implanted patients
before and after LVAD implantation. We hypothesized
that the SLAM would indicate relative LV filling pressures, and that it would increase in patients with endstage heart failure after CF-LVAD support.

Patients and Methods
Our echocardiographic database was queried randomly
for 60 non-intensive care unit patients with moderate-tosevere systolic dysfunction (LV ejection fraction [LVEF],
<0.35) on studies performed from January through
March 2010. In addition, the clinical records and echocardiograms of 81 adult recipients of the HeartMate II®
LVAD (Thoratec Corporation; Pleasanton, Calif ) from
January 2007 through December 2010 were evaluated
in a single-center, retrospective review. The retrospective
study was approved by the institutional review board of
the Washington University School of Medicine.
Echocardiographic Data

We reviewed parasternal and apical views, including
2-dimensional (2D), Doppler, and M-mode data obtained with use of the iE33 (Koninklijke Philips N.V.;
Best, The Netherlands) or the GE Vivid 7 ® ultrasound
system (GE VingMed Ultrasound AS; Horten, Norway). Doppler and 2D measurements included: LVEF
by means of the Simpson method, E point-septal separation (EPSS) in triplicate, LV end-diastolic and endsystolic diameters, peak early (E) transmitral filling velocity in diastole, early tissue septal and lateral annular
velocities (Ec), pulmonary artery pressure estimates by
tricuspid regurgitation velocity and inferior vena cava
size, and right ventricular outflow tract (RVOT) volume thickness index (VTI).4,11,12
The SLAM closure after the atrial phase of LV diastolic filling was obtained from 2D-guided M-mode
TTE images of the mitral valve in parasternal views
obtained at either a 66-mm/s or 100-mm/s sweep
speed. With use of ProSolv® software (FUJIF ILM Medical USA, Inc.; Stamford, Conn), the slope was calculated in cm/s between a point of inflection at which the
anterior mitral valve leaflet begins a downward descent
and another point at which it meets the posterior mitral
valve leaflet, closing the mitral valve. Figure 1 shows an
illustration of the methodology and actual image measurements. The slope was obtained at the underside of
the valve for thickened anterior mitral valve leaflets, at
which the image contrast between the valve space and
valve tissue is greatest. If the downward descent of the A
wave contained a “B-bump,” the slope remained calculated from the inflection of the A-wave descent to mitral
valve closure. We included only patients for whom at
Texas Heart Institute Journal

least 3 cardiac cycles were available, in order to generate a mean SLAM for each patient’s study. Our LVAD
analysis of SLAM was obtained only on those patients
for whom we had paired before- and after-implantation
data. After-implantation data were obtained in patients
in the ambulatory setting or who were readmitted for
reasons other than exacerbation of congestive heart failure (CHF) . Patients were excluded for atrial fibrillation
or flutter, mechanical mitral valves, excessive artifact
from bioprosthetic valve struts, and poor image quality that precluded slope analysis. The slope is negative;
however, for clarity, the slope in this article is expressed
as an absolute value with SD, obviating the need for a
preceding negative sign (–).
Serum Pro-Brain Natriuretic
Peptide Measurement

Serum pro-brain natriuretic peptide (BNP) levels (pg/
mL) were obtained retrospectively for LVAD patients
during the patients’ hospital admission before LVAD
implantation, and either before discharge from the hospital or at a follow-up hospital admission or outpatient
appointment. All samples were analyzed by the institutional core laboratory.
Diuretic Requirement

The diuretic requirement for each patient was collected
before and after LVAD surgery. Furosemide intravenous
(IV)-equivalent dosing was calculated in such a manner
that 40 mg of IV furosemide was equivalent to 80 mg
of oral furosemide, 20 mg of IV torsemide, or 1 mg of
IV bumetanide.13-16
SLAM in the Presence of
Acute Heart Failure Exacerbation

We next sought to examine the usefulness of SLAM as
an indicator of clinical status in CF-LVAD–supported
patients. Through detailed chart reviews, we analyzed
the SLAM of patients readmitted for CHF during the
study period who had suitable echocardiographic images before LVAD implantation, after LVAD implantation in an ambulatory setting, and during the CHF readmission for analysis, according to discharge diagnosis.
Statistical Methods

All tests for significance were conducted at the 5% error
rate (P=0.05). Analysis was conducted with use of SAS
software version 9.3 (SAS Institute Inc.; Cary, NC).
Change in the M-mode slope from before LVAD implantation to after-implantation and upon readmission
for heart-failure symptoms was determined by means
of a paired t test. Only LVAD patients for whom we
had paired measurements and 3 cycles per condition
were included in this part of the analysis. Reproducibility was analyzed for inter- and intraobserver reliability by means of the intraclass correlation coefficient
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Fig. 1 Slope measurement methodology. A) The slope of the anterior mitral valve leaflet (SLAM) is measured at the point of inflection
of the A-wave descent in diastole. B) Example of the SLAM measured in a patient with increased left ventricular end-diastolic pressure, including the “B-bump.” C) Example of a steep SLAM. D) Two-dimensional–guided M-mode transthoracic echocardiogram of
the mitral valve (parasternal long-axis view) at 66-mm/s sweep speed. The SLAM is identified in red. E) The SLAM measurement at the
point of inflection, from the underside of the leaflet to the point of valve closure, as shown by the red line.

(ICC) and the Bland-Altman method.17 Before-to-after
LVAD changes for RVOT-VTI, BNP, diuretic requirement, pulmonary artery pressure, EPSS, and LV enddiastolic and end-systolic diameters were calculated by
means of the Student paired t tests. The correlation between PCWP and SLAM before LVAD implantation
was examined by means of the Pearson correlation coefficient. The Fisher exact test was used for categorical
variables in demographic categories.
Patients with moderate-to-severe systolic dysfunction
were combined with before- and after-LVAD patients,
to examine differences in mean SLAM between each
group. Analysis of covariance (ANCOVA) was conducted to adjust for age and sex. Group means and all paired
comparisons were on the basis of model results. A correction for multiple comparison tests was applied. Two
different ANCOVA models were built: one with LVAD
pre-implant SLAM values and one with LVAD postimplant SLAM values. Changes in SLAM and E/ec
from post-LVAD status to readmission were evaluated
by means of paired t tests. Only patients for whom we
264

had post-implant and readmission data were included
in this analysis.
The ability of SLAM to distinguish accurately between groups was evaluated by means of the area under
the receiver operating characteristic curve. Comparisons
were made between random patients with an LVEF
<0.35 and pre-LVAD patients. Sensitivity and specificity were determined, and an optimal cutpoint was chosen on the basis of the Youden index. The correlation
between SLAM, E/ec, and LVEF values was examined
by means of the Pearson correlation coefficient. Deviation from linearity was examined by means of scatter
plots and a regression model, including the quadratic
term for E/ec.

Results
SLAM in Patients with Moderate-to-Severe
Systolic Dysfunction

The SLAM, LVEF, and E/ec were first evaluated in
cohorts of patients who had at least moderately im-
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paired LVEF (<0.35). The median SLAM was 11.6
r 5.27 cm/s for patients with LVEF <0.35 (Table I).
Linear regression analysis revealed no significant correlation between SLAM and LVEF. Figure 2A shows
a representative M-mode TTE image of the SLAM in
a patient with an LVEF <0.35, and Figure 2B shows a
selected line for SLAM determination. To evaluate the
correlation of SLAM with estimated filling pressures
in these patients, the ratios of early transmitral velocity
(E) to the average of medial and lateral annular early
myocardial tissue Doppler velocities (ec) were plotted
against the SLAM values (Fig. 2C). The median E/ec
of patients with moderate-to-severe LV dysfunction was
16.3 r 7.74 and correlated significantly with the SLAM
in a linear fashion (r= –0.473, P=0.0001) (Fig. 2C).
Unsupported, randomly selected patients with moderately to severely depressed LVEFs therefore display a
correlation between SLAM and E/ec measurements,
and E/ec is well validated in this population to correlate
closely with LV filling pressures.5

A

B

Demographic Characteristics
of the LVAD Study Population

TABLE I. Random Patients with LVEF <0.35
Variable

LVEF <0.35 (N=60)

Age (yr)

54.3 r 15.74

Male sex

32 (53)

LVEF

0.22 r 0.53

SLAM (cm/s)

11.6 r 5.27

E/ec ratio

16.2 r 7.74

Calculated PCWP (mmHg)

22 r 9.59

E = Early diastolic mitral velocity; ec = mitral annular tissue
velocity; LVEF = left ventricular ejection fraction; PCWP =
pulmonary capillary wedge pressure; SLAM = slope of the
anterior mitral valve leaflet
Values are expressed as mean r SD or as number and
percentage.
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P=0.0001
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We identified 81 LVAD patients who had undergone
HeartMate II implantation at our institution. They
were predominantly male (79%) and white (72%),
with a median age of 53.8 r 13.05 years (Table II).
Approximately one third had diabetes mellitus at the
time of implantation, and the cause of heart failure was
nonischemic cardiomyopathy in 54%. We were unable
to obtain the SLAM for 39 of these patients because
of atrial fibrillation (n=7), lack of before-implantation
TTE studies (n=5), lack of after-implantation TTE
studies (n=8), mechanical mitral valves (n=3), uninterpretable images of the mitral valve in 2D or M mode
(n=7), and fewer than 3 cardiac cycles for the before- or
after-LVAD windows (n=9).

25
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Fig. 2 Slope of the anterior mitral leaflet (SLAM): LVEF <0.35
and correlation with E/ec. A) M-mode transthoracic echocardiographic image of the mitral valve in a patient with a left ventricular ejection fraction (LVEF) <0.35. B) One diastolic cycle of
the same M-mode image of the mitral valve with the visualized
SLAM. C) Plot of E/ec and SLAM in patients with an LVEF <0.35,
(r= –0.473, P=0.0001). P <0.05 was considered statistically
significant.
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Echocardiographic and Laboratory Values
Before and After LVAD Implantation

We next evaluated currently accepted echocardiographic and clinical values of heart failure in the CF-LVAD–
supported patient group both before and after LVAD
implantation (Table III). Consistent with the medical
literature,18,19 the LV end-diastolic and end-systolic dimensions and estimated pulmonary artery pressures decreased by approximately 20% to 30% after LVAD implantation (P <0.001). The EPSS decreased an average
of 28.5% (from 2.5 to 1.8 cm) after LVAD implantation
(P <0.0001). The RVOT-VTI significantly increased
after LVAD implantation (P <0.0001), which was similar to increases in prior studies.20 In addition, our patient
population showed a reduction in BNP similar to that
in other institutional populations after LVAD surgery,
from an average of 1,715 to 305 pg/mL (P <0.0001).8
Concomitant with a decrease in BNP, diuretic dosing
(expressed as roughly equivalent to IV furosemide) decreased from approximately 70 mg/d to 22 mg/d, at a
TABLE II. Characteristics of the 81 Patients with LVADs
Variable

Value

Age (yr)

53.8 r 13.05

Male sex

64 (79)

White

59 (73)

Black

22 (27)

Diabetes mellitus

26 (32)

Ischemic cardiomyopathy

37 (46)

LVADs = left ventricular assist devices
Values are expressed as mean r SD or as number and
percentage.

documented outpatient visit. These results indicate that,
after LVAD implantation, our patients experienced an
expected improvement in cardiac output and a decrease
in congestion.
We next sought to validate the SLAM value in the
sicker group of CHF patients who later received an
LVAD. Invasive hemodynamic data were available for 23
patients before LVAD implantation within 48 hours of
the TTE and SLAM measurement. The median beforeimplantation PCWP was 26 r 5.9 mmHg. In these patients, the average SLAM was 7 cm/s, which was significantly lower than the average SLAM in moderate-to-severe native heart failure (SLAM, 11.6 cm/s; P d0.0001).
Upon LVAD implantation, the E/ec value significantly
decreased from 19.4 r 8.72 to 13.3 r 10.91 (P=0.0042),
which was similar to a published observation in hemodynamically stable outpatients.19 The before-LVAD E/ec
ratio correlated significantly with the SLAM (r= –0.409,
P=0.0119), although the after-LVAD E/ec did not (r=
–0.249, P=0.1631). After LVAD implantation, the mean
SLAM of patients increased in steepness from 7.3 r 2.44
to 14.7 r 5.01 cm/s (n=42; P <0.0001) at a mean of 11
months after implantation (range, 5 d–47 mo) (Fig. 3).
Interobserver ICC values ranged from 0.864 to 0.932,
and intraobserver ICC values ranged from 0.881 to
0.908 (Table IV). The Bland-Altman graphs suggested
few to no differences between observer measurements,
and insignificant results were found upon testing for linearity (P >0.2 in all) (Fig. 4). Taken together, the ICC
and Bland-Altman analyses indicate that inter- and intraobservations are equally precise.
SLAM in LVAD Patients Admitted for
Congestive Heart Failure Exacerbation

During the study period, 13 patients with CF-LVADs
were readmitted for CHF exacerbation (Table V). Of

TABLE III. Comparison of Variables Before and After LVAD Implantation
Variable

N

Before LVAD

After LVAD

P Value*

M-mode SLAM (cm/s)

42

7.3 r 2.44

14.7 r 5.01

<0.0001

RVOT-VTI (cm)

54

6.5 r 3.07

9.8 r 2.75

<0.0001

BNP (pg/mL)

45

1,758.2 r 1,286.17

350.4 r 245.4

<0.0001

PASP (mmHg)

48

53.4 r 14.21

33.4 r 10.13

<0.0001

EPSS (cm)

43

2.6 r 0.59

1.8 r 0.76

<0.0001

LVEDD (cm)

54

6.8 r 1

5.5 r 1.46

<0.0001

LVESD (cm)

54

6.1 r 0.96

5 r 1.45

<0.0001

Furosemide IV requirement (mg/d)

60

69.8 r 54.16

21.7 r 21.41

<0.0001

BNP = pro-brain natriuretic peptide; EPSS = E-point septal separation; IV = intravenous; LVAD = left ventricular assist device;
LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter; PASP = pulmonary artery systolic
pressure; RVOT-VTI = right ventricular outflow tract-volume thickness index; SLAM = slope of the anterior mitral valve leaflet
*On the basis of paired t test
Values are expressed as mean r SD. P <0.05 was considered statistically significant.
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Fig. 3 Two-dimensional guided M-mode transthoracic echocardiograms show the mitral valve A) before left ventricular assist device
(LVAD) implantation and B) a steeper descending slope of the anterior mitral valve leaflet (SLAM) after implantation. C) Graph shows
raw SLAM data from 42 patients before LVAD implantation (7.3 r 2.44 cm/s) and after implantation (14.7 r 5.01 cm/s; P <0.0001).
P <0.05 was considered statistically significant.

TABLE IV. Inter- and Intraobserver Agreement for Before- and After-LVAD Measurements of SLAM
Bland-Altman

Intraclass Correlation

95% Limits
Variable

Bias

Lower

Upper

P Value

Coefficient

95% CI

0.25

–1.66

2.18

0.24

0.932

(0.842–0.971)

–1.03

–6.92

4.85

0.53

0.864

(0.709–0.939)

–0.09

–1.63

1.45

0.3

0.881

(0.65–0.963)

0.79

–2.11

3.69

0.96

0.908

(0.721–0.972)

Interobserver
Before
After
Intraobserver
Before
After

CI = confidence interval; LVAD = left ventricular assist device; SLAM = slope of the anterior mitral valve leaflet
P <0.05 was considered statistically significant.

these, 6 had correlative echocardiographic data before
and after LVAD implantation and after LVAD implantation with CHF-exacerbation symptoms with a
SLAM value, and 7 had echocardiographic data in these
3 conditions for E/ec. Comparison between echocardiograms obtained after LVAD placement without an
admission diagnosis of CHF, and at readmission for a
CHF exacerbation, revealed a significant decrease in
SLAM from 12 r 3.93 to 7.3 r 3.5 (P=0.041). Figure 5
shows representative findings in one patient who had a
suspected pump thrombosis. The E/ec ratio of these 13
patients displayed marked variability, and an increase in
E/ec from 15.9 r 11.04 to 19.04 r 14.42 was not statistically significant (P=0.112).
Distinguishing between Systolic
Dysfunction and Advanced Heart
Failure (before LVAD Placement)

Finally, we sought to identify a cutoff SLAM value to
distinguish between randomly selected systolic CHF patients with an LVEF <0.35 and advanced-CHF patients
Texas Heart Institute Journal

who needed LVAD support. After adjusting for age
and sex, we found that the SLAM of the before-LVAD
patients was significantly lower (7.1 cm/s; P <0.0001)
than that of randomly selected patients with an LVEF
<0.35 (Fig. 6A). A separate analysis of the after-LVAD
implantation patients also yielded a significant difference in SLAM between patients after LVAD placement
(14.5 cm/s; 95% CI, 13–16) and those with LVEF
<0.35 (11.6 cm/s; 95% CI, 10.4–12.8) (P=0.008). A
receiver operating characteristic analysis indicated that
SLAM could distinguish before-LVAD patients in endstage heart failure from the randomly selected patients
with an LVEF <0.35 at an area under the curve (AUC)
of 0.7742 (95% CI, 0.6853–0.8631). An AUC of 1.0
would suggest perfect accuracy, whereas an AUC of 0.5
would indicate that SLAM is no better than chance
(Fig. 6B). An optimal SLAM cutpoint of 10 cm/s, determined by means of Youden index analysis, had an
88% sensitivity and a 55% specificity at distinguishing patients with end-stage CHF in the before-LVAD
category from all patients with LVEF <0.35 (Table VI).
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B
Interobserver Difference

Interobserver Difference

A

–1

–5
P=0.24

P=0.53

–2

Pre-LVAD Average of SLAM Values (cm/s)

Post-LVAD Average of SLAM Values (cm/s)

D
Intraobserver Difference

Intraobserver Difference

C

–1

P=0.3

P=0.96

–2

–2

Pre-LVAD Average of SLAM Values (cm/s)

Post-LVAD Average of SLAM Values (cm/s)

Fig. 4 Graphs, showing Bland-Altman plots of interobserver agreement A) before and B) after left ventricular assist device (LVAD)
implantation, and intraobserver agreement C) before and D) after implantation, suggest few to no differences between observer
measurements; insignificant results were found upon testing for linearity. P d0.05 was considered statistically significant.
SLAM = slope of the anterior mitral valve leaflet

TABLE V. Comparison of 13 Patients after LVAD Implantation and at Hospital Readmission
Variable

No. Pts.

After LVAD

Readmission LVAD

P Value*

SLAM

6

12 r 3.93

7.3 r 3.5

0.0409

E/ec

7

15.9 r 11.04

19.04 r 14.42

0.1124

E = early diastolic mitral velocity; ec = mitral annular tissue velocity; LVAD = left ventricular assist device; Pts = patients; SLAM = slope
of the anterior mitral valve leaflet
*On the basis of paired t test
Values are expressed as mean r SD. P <0.05 was considered statistically significant.

Discussion
Noninvasive evaluation of LV filling values in LVADsupported patients is a vexing clinical problem. Continuous-flow LVADs unload the LV by pumping blood
from the LV apex to the ascending aorta. The consequences of apical surgical LVAD implantation and nearpulseless LVAD-driven blood flow with variable output
268

through the native aortic valve pose new challenges in
evaluating circulatory hemodynamic status with use
of noninvasive imaging. Currently accepted methods
for evaluating LV filling pressures, such as E/ec, might
at times be difficult to obtain or be unreliable because
of an acoustic artifact consequent to positioning the
transducer at the cardiac apex.20 In the present study,
we introduce the quantified SLAM—a novel echocar-
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C
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Fig. 5 M-mode transthoracic echocardiograms
of the mitral valve in a patient with congestive
heart failure symptoms show A) a view before
left ventricular assist device implantation with B) an
associated slope of the anterior mitral valve leaflet (SLAM)
of 5.3 cm/s; and C) a view after device implantation
with D) an associated SLAM of 19.3 cm/s. E) M-mode
image shows a SLAM of 11.9 cm/s in the same patient
after readmission to the hospital with congestive heart
failure symptoms.
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TABLE VI. Sensitivity and Specificity Analysis of SLAM in
Predicting Pre-LVAD Status versus LVEF <0.35

P <0.001

16

P <0.001

P=0.008

SLAM (cm/s)

Sensitivity

Specificity

Youden
Index

5

0.2143

0.9833

0.1976

6

0.3571

0.9667

0.3238

7

0.5238

0.8

0.3238

8

0.619

0.65

0.269

9

0.7857

0.6

0.3857

10

0.881

0.55

0.431

11

0.9286

0.4833

0.4119

12

0.9286

0.4333

0.3619

13

0.9762

0.35

0.3262

14

1

0.25

0.25

15

1

0.2167

0.2167

16

1

0.15

0.15

17

1

0.15

0.15

18

1

0.1

0.1

19

1

0.0667

0.0667

20

1

0.05

0.05

21

1

0.05

0.05

22

1

0.0333

0.0333

23

1

0.0333
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Fig. 6 A) Graph shows comparisons in slope of the anterior
mitral valve leaflet (SLAM) in 42 patients before left ventricular
assist device (LVAD) insertion, in the same 42 patients after
LVAD insertion, and in 60 different, randomly selected patients
without an LVAD but with left ventricular ejection fraction
(LVEF) <0.35. P <0.05 was considered statistically significant.
B) Receiver operating characteristic analysis indicates that the
SLAM can distinguish patients in end-stage heart failure and
before LVAD implantation from randomly selected patients with
an LVEF <0.35 at an area under the curve (AUC) of 0.7742 (95%
confidence interval, 0.6853–0.8631).

diographic measurement that in paired analyses appears
to correlate with LV unloading by an LVAD and is an
indicator of heart-failure clinical status both in native
heart failure and in patients with an implanted CFLVAD.
Our data suggest an inverse relationship between the
SLAM and LV filling pressures in LVAD-supported
and -unsupported hearts. The physiologic mechanisms
underlying this observation necessitate further investigation; however, we currently hypothesize the following
potentially contributory mechanisms. First, concomitant diastolic and moderate-to-severe systolic dysfunc270

LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; SLAM = slope of the anterior mitral valve leaflet
*The cutpoint of 10 cm/s distinguished random patients with
LVEF <0.35 from those in end-stage congestive heart failure
(pre-LVAD) with an 88% sensitivity and a 55% specificity.

tion (LVEF <0.35) has been shown in patients to result
in an increased LV end-diastolic pressure (LVEDP).10 In
those patients who have an elevated left atrial pressure, a
longer time would then be required for the ventricle to
generate a pressure greater than that in the atrium and
would thereby affect mitral valve closure. Investigators
who conducted prior invasive and hemodynamic studies
have reported a qualitatively prolonged transmitral flow
and delayed closure of the mitral valve in patients with
an elevated LVEDP, evidenced with use of M-mode
echocardiography.21 Poor LV contractile function correlates with a decreased rate of developed LV pressure
during systole (dP/dt) through the increase in time for
the ventricle to produce the Doppler jet of mitral regurgitation.22 Similar to SLAM, dP/dt has been shown
to improve by increasing upon CF-LVAD implanta-
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tion.8 Regardless of the cause of cardiomyopathy, a
high LVEDP and weak contractile function culminate
in ineffective unloading, which is consistent with the
delayed-closure physiology of the mitral valve observed
in M-mode echocardiography, and which in this study
was quantified as the SLAM.
In unsupported patients with LVEF <0.35, there was
a correlation between SLAM and E/ec measurements,
and E/ec is well validated and routinely used in this population to correlate closely with LV filling pressures.5,23
In addition, our data indicate that SLAM is able to
identify, with good sensitivity and specificity, patients
with a depressed LVEF who are sicker. A SLAM cutpoint value of <10 cm/s differentiates patients with
end-stage CHF who are clinically determined to need
LVAD support from a random cohort of patients with
LVEF <0.35. Although all echocardiographic values
should be analyzed within the clinical context of each
individual patient, a SLAM <10 cm/s or an appreciable
decrease in SLAM might trigger a change in medical
therapy or accelerate referral for advanced heart-failure
therapies.
The SLAM method appears to have a unique capacity to provide a metric of ventricular unloading in an
LVAD-supported population. The average SLAM of
patients with end-stage CHF doubled after LVAD implantation—and, in a limited subgroup analysis within
our data set, appeared to detect clinical deterioration
sensitively in patients with LVADs who were readmitted for CHF symptoms. The possible causes of CHF
exacerbations in an LVAD population are varied and
might include inadequate rotor speed and unloading
of the LV, or worsening of native heart failure. Each
of these complications would lead to a decrease in the
left atrial and LV gradients and prolong the closure of
the mitral valve. Regular evaluation of the SLAM after
LVAD implantation might provide the treating physician with a sensitive, noninvasive tool for rapidly evaluating the adequacy of LV unloading in these patients
who have complications. In addition, we anticipate that
SLAM might be used in future studies to adjust the
LVAD for clinical optimization and for long-term patient monitoring. Prospective analyses at fixed imaging
intervals after LVAD implantation will result in more
rigorous future validation of the SLAM method.
Study Limitations

This study has several important limitations. First, it
is a single-institution, retrospective study. Because the
SLAM was not prospectively collected, many patients
had insufficient echocardiographic images or cardiac
cycles from which to obtain the SLAM; and in some
cases, M-mode TTE of the mitral valve was not available. Furthermore, echocardiograms were obtained at
varying intervals postoperatively, and we were unable
to categorize them into consistent time-intervals for a
Texas Heart Institute Journal

thorough longitudinal study. We did not evaluate the
correlation between the SLAM and aortic valve opening
in LVAD patients, because aortic valve opening is also
variable, with an unknown mathematical correlation to
unloading.20,24 In addition, SLAM cannot be applied
to patients who have atrial fibrillation or flutter, a mechanical mitral valve, or poor 2D TTE windows that
preclude seeing the mitral valve in M mode.
Conclusion

We introduce the SLAM as a promising, novel, Mmode echocardiographic method of evaluating LV filling pressures, and we provide evidence to suggest that
it remains valid in patients with a CF-LVAD. This
method adds to an expanding panel of echocardiographic methods that are used to evaluate LV unloading
in LVAD recipients. Further echocardiographic studies
are needed to determine the usefulness of SLAM in
other patient populations and to establish a time course
of dynamic changes of echocardiographic values within
the post-implantation LVAD population toward LVAD
optimization, clinical status, and outcomes.
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